The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Summer 2022 RFP: Accelerating the Translation of Parkinson's Disease Therapies, 2022Evaluating the Ability of HSG4112, An Anti-obesity Drug Candidate, to Protect Dopamine-producing Neurons Against Mitochondrial Dysfunction
Study Rationale: Mitochondrial dysfunction in dopamine-producing neurons is one of the hallmarks of Parkinson’s disease (PD) pathology. Inside mitochondria is a protein called Paraoxonase 2 (PON2)...
-
Research Grant, 2022WATCH-PD Remote Digital Health Technology Extension: Planning Period
Study Rationale: In the WATCH-PD study, we evaluated the use of wearable digital devices to monitor symptoms and quality of life in individuals with early, untreated Parkinson’s disease (PD). This...
-
Research Grant, 2022Development of a Safe and Efficient Method to Treat Parkinson’s Disease Using RNA-based Gene Therapy
Study Rationale: Gene mutations are one of several cause of Parkinson’s disease (PD). Developing an efficient method for introducing functional versions of these mutated genes into cells that are...
-
Research Grant, 2022Identifying Bothersome Symptoms, Impacts of Disease and Relevance of WATCH-PD Digital Measures Over Time in Early Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is a devastating neurologic disease and current treatments are unable to prevent the worsening of symptoms. One problem in developing new therapies has been...
-
Research Grant, 2022Interaction of Mitochondrial Genes and Lifestyle Factors on Age at Onset in Parkinson’s Disease
Study Rationale: Cellular structures called mitochondria are functionally impaired in Parkinson’s disease (PD). How environmental toxins or lifestyle factors influence mitochondrial function and...
-
Therapeutic Pipeline Program, 2022Evaluating the Efficacy of a mGluR5 Modulator in Preclinical Models of Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is one of many neurodegenerative diseases that are characterized by the buildup of misfolded protein aggregates in the brain. Preclinical data suggest that...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.